Pacira BioSciences (PCRX) EBT (2010 - 2026)

Pacira BioSciences' EBT history runs 17 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• On a quarterly basis, EBT fell 42.59% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $13.2 million, a 119.35% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, up 126.74% from the prior year.
• EBT climbed to $5.0 million in Q1 2026 per PCRX's latest filing, from $571000.0 in the prior quarter.
• Across five years, EBT topped out at $37.9 million in Q2 2023 and bottomed at -$138.9 million in Q3 2024.
• The 5-year median for EBT is $8.7 million (2025), against an average of $2.0 million.
• Across the five-year window, EBT jumped 702.37% in 2023 and sank 936.43% in 2024, its largest moves.
• Year by year, EBT stood at -$18.1 million in 2022, then soared by 286.63% to $33.7 million in 2023, then declined by 24.3% to $25.5 million in 2024, then tumbled by 97.76% to $571000.0 in 2025, then jumped by 775.31% to $5.0 million in 2026.
• Per Business Quant, the three latest PCRX EBT figures stand at $5.0 million (Q1 2026), $571000.0 (Q4 2025), and $9.5 million (Q3 2025).